Repositive, the company that created a portal for accessing human genomic research data, has closed a Series A funding round of GBP2.5 million.
The investors include lead investor Ananda Social Venture Fund and Force Over Mass Capital.
Amadeus Capital Partners and Jonathan Milner are increasing their investments, having previously participated in seed funding Repositive.
This brings the total funds raised to date in Repositive to GBP3.3 million.
Fiona Nielsen, CEO of Repositive, says: “This investment will allow Repositive to expand its commercial offering through the development of premium features for our fast growing community of platform users worldwide. Alongside this, we will invest further in expanding the range of data sources on our platform and developing further commercial products and services for the genomics R&D industry. I am delighted to welcome Ananda as lead investor and to see the continued support of Amadeus Capital Partners and Jonathan Milner.”
Lennart Hergel, investment director for Ananda Social Venture Fund, says: “Repositive is unique in identifying, providing access and democratising genomic data without ethical compromise. We believe that this will reduce time and cost for diagnostics and drug development, therefore enabling better and affordable access to new and personalised therapies for patients. We have confidence that the energetic and capable Repositive team will drive this impact and create a very successful company on a commercial level."
Milner adds: “Repositive have made great progress in building their platform and the community it supports. With plans to commercialise the platform this year, Repositive are in a strong position to become a commercial and scientific global success.”
Pierre Socha, principal, Amadeus Capital Partners, says: “Since the initial seed funding round, the Repositive team has made excellent progress in developing its platform. With a growing user base, including many of the world’s largest pharma companies, and a series of global partnerships, Repositive is strongly positioned for future growth.”
Since its launch in September 2016, the community-driven Repositive platform has grown to over one million data sets and the company has expanded their global user base across pharma, biotech and academia. Alongside this, the company has secured a number of significant partnerships with leading genetic research and pharma companies in oncology, through the Repositive PDX Consortium.
